#MarksansPharma @53
A strong formulation player with manufacturing facilities in UK, USA, and India.
The product portfolio covers pain, diabetes, cardiovascular, cough-cold, GI and CNS, etc.
A significant increase in margins along with revenue (30%) led to 100% profit growth for 9MF21.
55% revenue comes from over-the-counter (OTC) products, 95% revenue from regulated markets (US, Canada, Europe, Australia). Both are unique features.
Forward integrated business model, recently announced backward integration in API manufacturing for captive consumption.
In the niche soft gel capsule segment, the company holds many patents.
Soft gel is a high entry barrier segment, with less competition due to high CAPEX requirements.
Southport, UK facility is awaiting USFDA approval to export in the USA.
195 Cr Cash, debt-free, significant improvement in revenue and profit in last three years.
The company has 450+ formulations in markets, planning to add adding 50+ products every year.
The company is highly undervalued compared to its peers..
Find You Trade
Trade As Per Ur RR
Shared for educational purposes